Published online December 1, 2005
PEDIATRICS Vol. 116 No. 6 December 2005, pp. 1361-1366 (doi:10.1542/10.1542/peds.2005-0293)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sperandio, M.
Right arrow Articles by Linderkamp, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sperandio, M.
Right arrow Articles by Linderkamp, O.
Related Collections
Right arrow Premature & Newborn
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Effectiveness and Side Effects of an Escalating, Stepwise Approach to Indomethacin Treatment for Symptomatic Patent Ductus Arteriosus in Premature Infants Below 33 Weeks of Gestation

Markus Sperandio, MD*, Bernd Beedgen, MD*, Reinhard Feneberg, MD*,{ddagger}, Christina Huppertz, MD*, Jürgen Brüssau, MD*, Johannes Pöschl, MD* and Otwin Linderkamp, MD*

* Division of Neonatology, Department of Pediatrics
{ddagger} Coordination Center for Clinical Trials, University of Heidelberg, Heidelberg, Germany

Objective. Symptomatic patent ductus arteriosus (sPDA) is a common problem in premature infants and can be treated effectively with intravenous indomethacin, leading to permanent ductal closure in 70% to 80% of infants. Infants who do not respond to pharmacologic closure of the duct ultimately have to undergo surgical or interventional closure of the PDA. Optimizing the pharmacologic treatment could offer an interesting approach to reduce the number of infants who need surgical closure of the duct.

Methods. We conducted a retrospective analysis in infants who were <33 weeks’ gestation, had sPDA, and were treated with high-dose intravenous indomethacin. From 1993 to 2002, 129 infants with sPDA received indomethacin after diagnosis of sPDA was confirmed by echocardiography. Treatment was started in all infants with intravenous indomethacin (0.2 mg/kg given 5 times at 0 hours, 12 hours, 24 hours, 48 hours, and 72 hours). When the ductus was still open at 36 hours, indomethacin every 12 hours was continued and single doses increased up to 1 mg/kg until ductal closure was achieved.

Results. In 68 (53%) of 129 infants who were treated with indomethacin, ductal closure occurred during intermediate-dose indomethacin therapy (up to 1.5 mg/kg total dose). In the 61 initial nonresponders, the continuation of indomethacin led to ductal closure in 59 infants. When infants who were treated with an intermediate dose were compared with the initial nonresponders, no differences in the incidences of renal or electrolyte abnormalities, gastrointestinal bleeding, intraventricular hemorrhage, or periventricular leukomalacia were found.

Conclusions. High-dose indomethacin after intermediate-dose therapy resulted in an overall closure rate of 98.5% (127 of 129). Although single indomethacin doses of up to 1 mg/kg were given, high-dose indomethacin was safe.

Key Words: patent ductus • indomethacin • premature infants

Abbreviations: sPDA, symptomatic patent ductus arteriosus • GI, gastrointestinal • NEC, necrotizing enterocolitis

Accepted Apr 12, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
J T Attridge, D A Kaufman, and D S Lim
B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus
Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2009; 94(3): F178 - F182.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. C. Madan, D. Kendrick, J. I. Hagadorn, I. D. Frantz III, and the National Institute of Child Health and Human D
Patent Ductus Arteriosus Therapy: Impact on Neonatal and 18-Month Outcome
Pediatrics, February 1, 2009; 123(2): 674 - 681.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
P. V. Gordon
Reopening the debate on corticosteroids: to the editor.
Pediatrics, June 1, 2006; 117(6): 2318 - 2320.
[Full Text] [PDF]

Home page
 PediatricsHome page
S. Manzar
High-Dose Indomethacin for Patent Ductus Arteriosus Closure: How Strong Is the Evidence?
Pediatrics, May 1, 2006; 117(5): 1863 - 1863.
[Full Text] [PDF]

Home page
 PediatricsHome page
M. Sperandio, B. Beedgen, and O. Linderkamp
High-Dose Indomethacin for Patent Ductus Arteriosus Closure: How Strong Is the Evidence?: In Reply
Pediatrics, May 1, 2006; 117(5): 1863 - 1864.
[Full Text] [PDF]